Efavirenz and retinal toxicity
It is reported that the patient started on Efavirenz (a non-nucleoside reverse transcriptase inhibitor) in March 1999. Three months later he began to experience blurred vision. The Efavirenz was discontinued, but the patient's vision continued to deteriorate to a visual acuity of 6/60 in both eyes. The case report notes 'ophthalmoscopy showed an area of retinal opacification occupying most of his macula in both eyes'.
The authors have attributed this visual loss to Efavirenz.
In a large primary and tertiary referral centre in London (Chelsea and Westminster Hospital), 683 patients have received Efavirenz since December 2000 as part of their HIV treatment. Only 19 of the 683 patients on Efavirenz have had ocular symptoms requiring review. None of these patients have any signs or symptoms corresponding with those reported as Efavirenz toxicity. The ocular pathology found in these cases was attributable to CMV disease (excluding the case of Best Vitelliform Macular Dystrophy) and is represented in Table 1 .
Efavirenz is a relatively new drug. To date its known side effects are neuropsychological (dizziness/light-headedness, vivid dreams/nightmares) and dermatological (skin rash). Of 683 patients treated with Efavirenz at this centre, none had ocular pathology attributable to the drug itself.
These findings would lead us to conclude that many In their recent paper, Baker and Grey described five cases of benign 'idiopathic' haemorrhagic retinopathy. 1 I would argue, however, that Case 2 is almost certainly suffering from altitude retinopathy. The 44-year-old woman described had 2 days previously flown in a pressurized aircraft from Australia. The authors dismiss altitude retinopathy because altitude sickness 'does not occur in pressurized aircraft' and does not have a 'delayed onset'. In fact, cabin pressures in commercial aircraft are usually equivalent to 9000 ft, representing a fall in inspired pO 2 of 30%. 2 The mild anaemia of Case 2 and the long duration of flight may have made her particularly susceptible to this hypoxia. Also altitude retinopathy has been shown to occur in the absence of altitude sickness in a prospective study analysing these conditions independently at altitude. climber taken 5 days after descent from Mount Everest is shown for comparison (Figure 1 ). This climber also had no symptoms of altitude sickness and the haemorrhages cleared without long-term sequellae.
Altitude retinopathy is a poorly understood condition, due in part to the remoteness at which it usually occurs and the difficulties in performing invasive ophthalmological tests at altitude. It may be that the authors need to be congratulated for the first reported case following travel in a commercial jet aircraft.
I read with interest the article on 'one-stop' cataract surgery. 1 I agree that such a system reduces the number of hospital attendances and thereby provides more effective use of time and resources. The ophthalmic unit at Warrington General Hospital is currently in the process of expansion with the addition of a new theatre dedicated to high volume cataract surgery based on a similar 'fast track' system and is keen on learning from the experiences of others using such a system.
I am concerned at the poor theatre utilisation reported and the high rate of inappropriate GOS18 and GP referrals thereby defeating the very purpose of 'one-stop' surgery. Perhaps if optometrists were to be provided with referral guidelines and exclusion criteria, this might be avoided. It is also surprising that up to 9% of patients refused same day surgery in spite of having been sent a letter stating that they should be prepared for this.
